Search

Your search keyword '"Juliusson, Gunnar"' showing total 941 results
Start Over Author "Juliusson, Gunnar"
941 results on '"Juliusson, Gunnar"'

152. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Author

Baliakas, Panagiotis, primary, Mattsson, Mattias, additional, Hadzidimitriou, Anastasia, additional, Minga, Eva, additional, Agathangelidis, Andreas, additional, Sutton, Lesley-Ann, additional, Scarfo, Lydia, additional, Davis, Zadie, additional, Yan, Xiao-Jie, additional, Plevova, Karla, additional, Sandberg, Yorick, additional, Vojdeman, Fie J., additional, Tzenou, Tatiana, additional, Chu, Charles C., additional, Veronese, Silvio, additional, Mansouri, Larry, additional, Smedby, Karin E, additional, Giudicelli, Véronique, additional, Nguyen-Khac, Florence, additional, Panagiotidis, Panagiotis, additional, Juliusson, Gunnar, additional, Anagnostopoulos, Achilles, additional, Lefranc, Marie-Paule, additional, Trentin, Livio, additional, Catherwood, Mark, additional, Montillo, Marco, additional, Niemann, Carsten U., additional, Langerak, Anton W., additional, Pospisilova, Sarka, additional, Stavroyianni, Niki, additional, Chiorazzi, Nicholas, additional, Oscier, David, additional, Jelinek, Diane F, additional, Shanafelt, Tait, additional, Darzentas, Nikos, additional, Belessi, Chrysoula, additional, Davi, Frederic, additional, Ghia, Paolo, additional, Rosenquist, Richard, additional, and Stamatopoulos, Kostas, additional

Published
2017
Full Text
View/download PDF

154. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells

Author

Eriksson, Mia, primary, Peña-Martínez, Pablo, additional, Ramakrishnan, Ramprasad, additional, Chapellier, Marion, additional, Högberg, Carl, additional, Glowacki, Gabriella, additional, Orsmark-Pietras, Christina, additional, Velasco-Hernández, Talía, additional, Lazarević, Vladimir Lj, additional, Juliusson, Gunnar, additional, Cammenga, Jörg, additional, Mulloy, James C., additional, Richter, Johan, additional, Fioretos, Thoas, additional, Ebert, Benjamin L., additional, and Järås, Marcus, additional

Published
2017
Full Text
View/download PDF

156. Biliary tract malignancies: a population-based study on incidence, prognosis and management of patients

Author

Juliusson, Gunnar, Jonasson, Jon Gunnlaugur, Jonsdottir, Sara B., Garcia, Henrik G., Elinborg Olafsdottir, Pall Helgi Möller, and Björnsson, Einar S.

Abstract

Background: Biliary tract malignancies are uncommon and few population-based studies are available. Methods: This nationwide population-based study in Iceland included all patients diagnosed with intra- and extrahepatic cholangiocarcinoma, gallbladder and ampullary cancer from 1984 to 2012. Patients were identified through the Icelandic Cancer Registry. Clinical information was obtained from patient records. Results: Overall 245 patients were identified: 38 had intrahepatic cholangiocarcinoma, 66 extrahepatic cholangiocarcinoma, 73 gallbladder cancer (GBC) and 68 ampullary cancer. Overall incidence for bile tract malignancies was 1–3 per 100,000 person-years and less than 1 by sub-type. The overall bile tract malignancies in males increased from 1.3 (95% CI 0.8–1.8) to 2.5 (1.9–3.1) per 100,000 inhabitants. The incidence of GBC among females decreased from 1.1 (0.7–1.5) to 0.5 (0.2–0.7). Surgery decreased for extrahepatic cholangiocarcinoma (56 to 23%, p = .027), ampullary cancer (80 to 48%, p = .03) and overall bile tract cancer (61 to 32%, p p Conclusions: Overall incidence of bile tract malignancies increased in males and GBC decreased in women. Long-term survival is poor and did not improve despite changes in treatment.

Published
2016
Full Text
View/download PDF

157. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Author

Baliakas, Panagiotis, Agathangelidis, Andreas, Hadzidimitriou, Anastasia, Sutton, Lesley-Ann, Minga, Eva, Tsanousa, Athina, Scarfò, Lydia, Davis, Zadie, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Sandberg, Yorick, Vojdeman, Fie Juhl, Boudjogra, Myriam, Tzenou, Tatiana, Chatzouli, Maria, Chu, Charles C., Veronese, Silvio, Gardiner, Anne, Mansouri, Larry, Smedby, Karin E., Pedersen, Lone Bredo, Moreno, Denis, Van Lom, Kirsten, Giudicelli, Véronique, Francova, Hana Skuhrova, Nguyen-Khac, Florence, Panagiotidis, Panagiotis, Juliusson, Gunnar, Angelis, Lefteris, Anagnostopoulos, Achilles, Lefranc, Marie-Paule, Facco, Monica, Trentin, Livio, Catherwood, Mark, Montillo, Marco, Geisler, Christian H., Langerak, Anton W., Pospisilova, Sarka, Chiorazzi, Nicholas, Oscier, David, Jelinek, Diane F., Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Ghia, Paolo, Rosenquist, Richard, and Stamatopoulos, Kostas

Published
2015
Full Text
View/download PDF

158. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, additional, Kavakiotis, Ioannis, additional, Agathangelidis, Andreas, additional, Sutton, Lesley-Ann, additional, Minga, Eva, additional, Ntoufa, Stavroula, additional, Tausch, Eugen, additional, Yan, Xiao-Jie, additional, Shanafelt, Tait, additional, Plevova, Karla, additional, Boudjogra, Myriam, additional, Rossi, Davide, additional, Davis, Zadie, additional, Navarro, Alba, additional, Sandberg, Yorick, additional, Vojdeman, Fie Juhl, additional, Scarfo, Lydia, additional, Stavroyianni, Niki, additional, Sudarikov, Andrey, additional, Veronese, Silvio, additional, Tzenou, Tatiana, additional, Karan-Djurasevic, Teodora, additional, Catherwood, Mark, additional, Kienle, Dirk, additional, Chatzouli, Maria, additional, Facco, Monica, additional, Bahlo, Jasmin, additional, Pott, Christiane, additional, Pedersen, Lone Bredo, additional, Mansouri, Larry, additional, Smedby, Karin E., additional, Chu, Charles C., additional, Giudicelli, Véronique, additional, Lefranc, Marie-Paule, additional, Panagiotidis, Panagiotis, additional, Juliusson, Gunnar, additional, Anagnostopoulos, Achilles, additional, Vlahavas, Ioannis, additional, Antic, Darko, additional, Trentin, Livio, additional, Montillo, Marco, additional, Niemann, Carsten, additional, Döhner, Hartmut, additional, Langerak, Anton W., additional, Pospisilova, Sarka, additional, Hallek, Michael, additional, Campo, Elias, additional, Chiorazzi, Nicholas, additional, Maglaveras, Nikos, additional, Oscier, David, additional, Gaidano, Gianluca, additional, Jelinek, Diane F., additional, Stilgenbauer, Stephan, additional, Chouvarda, Ioanna, additional, Darzentas, Nikos, additional, Belessi, Chrysoula, additional, Davi, Frederic, additional, Hadzidimitriou, Anastasia, additional, Rosenquist, Richard, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2017
Full Text
View/download PDF

159. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma

Author

Jain, Neeraj, primary, Hartert, Keenan, additional, Tadros, Saber, additional, Fiskus, Warren, additional, Havranek, Ondrej, additional, John Ma, Man-Chun, additional, Bouska, Alyssa, additional, Heavican, Tayla, additional, Kumar, Dhiraj, additional, Deng, Qing, additional, Moore, Dalia, additional, Pak, Christine, additional, Liu, Chih Long, additional, Gentles, Andrew, additional, Hartmann, Elena, additional, Kridel, Robert, additional, Smedby, Karin Ekstrom, additional, Juliusson, Gunnar, additional, Rosenquist, Richard, additional, Gascoyne, Randy D., additional, Rosenwald, Andreas, additional, Giancotti, Filippo, additional, Neelapu, Sattva S., additional, Westin, Jason, additional, Vose, Julie, additional, Lunning, Matthew, additional, Greiner, Timothy, additional, Rodig, Scott, additional, Iqbal, Javeed, additional, Alizadeh, Ash, additional, Davis, R. Eric, additional, Bhalla, Kapil, additional, and Green, Michael R., additional

Published
2017
Full Text
View/download PDF

160. Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry

Author

Lazarevic, Vladimir Lj, primary, Rosso, Aldana, additional, Juliusson, Gunnar, additional, Antunovic, Petar, additional, Derolf, Åsa Rangert, additional, Deneberg, Stefan, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Wennström, Lovisa, additional, Wahlin, Anders, additional, Höglund, Martin, additional, Lehmann, Sören, additional, and Johansson, Bertil, additional

Published
2017
Full Text
View/download PDF

161. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

Author

Wichert, Stina, primary, Juliusson, Gunnar, additional, Johansson, Åsa, additional, Sonesson, Elisabeth, additional, Teige, Ingrid, additional, Wickenberg, Anna Teige, additional, Frendeus, Björn, additional, Korsgren, Magnus, additional, and Hansson, Markus, additional

Published
2017
Full Text
View/download PDF

162. Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors

Author

Baliakas, Panagiotis, primary, Moysiadis, Theodoros, additional, Hadzidimitriou, Anastasia, additional, Xochelli, Aliki, additional, Mattsson, Mattias, additional, Sutton, Lesley-Ann, additional, Minga, Eva, additional, Scarfo, Lydia, additional, Rossi, Davide, additional, Davis, Zadie, additional, Agathangelidis, Andreas, additional, Villamor, Neus, additional, Parker, Helen, additional, Kotaskova, Jana, additional, Stalika, Evangelia, additional, Plevova, Karla, additional, Mansouri, Larry, additional, Cortese, Diego, additional, Lopez, Alba Navaro, additional, Delgado, Julio, additional, Larrayoz, Marta, additional, Young, Emma, additional, Anagnostopoulos, Achilles, additional, Smedby, Karin E, additional, Juliusson, Gunnar, additional, Catherwood, Mark, additional, Strefford, Jonathan C, additional, Stavroyianni, Niki, additional, Belessi, Chrysoula, additional, Pospisilova, Sarka, additional, Oscier, David, additional, Gaidano, Gianluca, additional, Campo, Elias, additional, Ghia, Paolo, additional, Rosenquist, Richard, additional, and Stamatopoulos, on behalf of ERIC, Kostas, additional

Published
2016
Full Text
View/download PDF

163. A Distributed International Patient Data Registry for Hairy Cell Leukemia

Author

Andritsos, Leslie A., primary, Grever, Michael R., additional, Anghelina, Mirela, additional, Dearden, Claire E, additional, Else, Monica, additional, Blachly, James S., additional, Lele, Omkar, additional, Ravandi, Farhad, additional, Zent, Clive S, additional, Johnston, James B., additional, Banerji, Versha, additional, Forconi, Francesco, additional, Ho, Anthony D., additional, Zenz, Thorsten, additional, Dietrich, Sascha, additional, Demeter, Judit, additional, Barrientos, Jacqueline C., additional, Burger, Jan A., additional, Call, Timothy G., additional, Chiorazzi, Nicholas, additional, DeAngelo, Daniel J., additional, Delgado, Julio, additional, Fagarasanu, Andrei, additional, Falini, Brunangelo, additional, Gozzetti, Alessandro, additional, Jones, Jeffrey, additional, Juliusson, Gunnar, additional, Kraut, Eric H., additional, Kreitman, Robert J., additional, Larratt, Loree, additional, Lauria, Francesco, additional, Lozanski, Gerard, additional, Montserrat, Emili, additional, Parikh, Sameer A., additional, Park, Jae H., additional, Polliack, Aaron, additional, Quest, Graeme R., additional, Rai, Kanti R., additional, Robak, Tadeusz, additional, Saven, Alan, additional, Tadmor, Tamar, additional, Tallman, Martin S., additional, Tam, Constantine S., additional, Tiacci, Enrico, additional, Troussard, Xavier, additional, Abdel-Wahab, Omar, additional, Zinzani, Pier Luigi, additional, Heckler, Christopher, additional, and Payne, Philip R.O., additional

Published
2016
Full Text
View/download PDF

165. DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma

Author

Hartert, Keenan, primary, Tadros, Saber, additional, Bouska, Alyssa, additional, Moore, Dalia, additional, Pak, Christine, additional, Heavican, Tayla, additional, Liu, Chih Long, additional, Gentles, Andrew J., additional, Hartmann, Elena M, additional, Kridel, Robert, additional, Smedby, Karin Ekstrom, additional, Juliusson, Gunnar, additional, Rosenquist, Richard, additional, Gascoyne, Randy D, additional, Rosenwald, Andreas, additional, Bast, Martin, additional, Vose, Julie M, additional, Lunning, Matthew, additional, Greiner, Timothy C., additional, Rodig, Scott J, additional, Iqbal, Javeed, additional, Levy, Ronald, additional, Alizadeh, Ash A., additional, and Green, Michael R, additional

Published
2016
Full Text
View/download PDF

167. The prognostic impact of FLT3-ITD and NPM1mutation in adult AML is age-dependent in the population-based setting

Author

Juliusson, Gunnar, Jädersten, Martin, Deneberg, Stefan, Lehmann, Sören, Möllgård, Lars, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Lorenz, Fryderyk, Ölander, Emma, Lazarevic, Vladimir Lj, and Höglund, Martin

Abstract

In acute myeloid leukemia (AML) FLT3internal tandem duplication (ITD) and nucleophosmin 1 (NPM1) mutations provide prognostic information with clinical relevance through choice of treatment, but the effect of age and sex on these molecular markers has not been evaluated. The Swedish AML Registry contains data on FLT3-ITD and NPM1mutations dating to 2007, and 1570 adult patients younger than 75 years, excluding acute promyelocytic leukemia, had molecular results reported. Females more often had FLT3ITDand/or NPM1mut(FLT3ITD: female, 29%; male, 22% [P= .0015]; NPM1mut: female, 36%; male, 27% [P= .0001]), and more males were double negative (female, 53%; male, 64%; P< .0001). Patients with FLT3ITDwere younger than those without (59 vs 62 years; P= .023), in contrast to patients with NPM1mut(62 vs 60 years; P= .059). Interestingly, their prognostic effect had a strong dependence on age: FLT3ITDindicated poor survival in younger patients (<60 years; P= .00003), but had no effect in older patients (60-74 years; P= .5), whereas NPM1mutindicated better survival in older patients (P= .00002), but not in younger patients (P= .95). In FLT3ITD/NPM1mutpatients, the survival was less dependent on age than in the other molecular subsets. These findings are likely to have clinical relevance for risk grouping, study design, and choice of therapy.

Published
2020
Full Text
View/download PDF

168. Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Author

Ngai, Lok Lam, Veenstra, Coen R., Gradowska, Patrycja, Kelder, Angèle, Scholten, Willemijn, Snel, Alexander N., Tettero, Jesse M., Bachas, Costa, Breems, Dimitri, Fischer, Thomas, Gjertsen, Bjorn T., Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Alhan, Canan, Westers, Theresia M., Valk, Peter J. M., de Leeuw, David C., Lowenberg, Bob, Ossenkoppele, Gert, Cloos, Jacqueline, and van de Loosdrecht, Arjan A.

Abstract

Diagnosis of myelodysplastic syndromes (MDS) and accurate risk assessment to tailor treatment remains challenging. High-risk MDS (hrMDS) patients who are fit enough may benefit from intensive chemotherapy followed by post-remission consolidation. The HOVON-SAKK (HO) acute myeloid leukemia (AML) trials, designed to test novel drug combinations with an intensive treatment regimen, included hrMDS patients (RAEB and RAEB-T). Since these HO-trials have been executed with large patient cohorts for many years, they offer the unique possibility to study the outcome, risk classification, and relevance of measurable residual disease (MRD) in hrMDS. A pooled database is available from HOVON-SAKK of patients who were treated with intensive chemotherapy (studies containing MDS patients with IPSS ≥ 1.5 HO42A, HO81, HO92, HO102, and IPSS-R > 4.5 HO103, HO132).

Published
2023
Full Text
View/download PDF

169. Vaccine-Preventable Infections in Multiple Myeloma: A Population-Based Study on 8672 Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Author

Einarsdottir, Sigrun, Sverrisdottir, Ingigerdur, Villegas Scivetti, Mariana, Day, Christopher, Turesson, Ingemar, Juliusson, Gunnar, Carlson, Kristina Elisabet, Larfors, Gunnar, and Blimark, Cecilie Hveding

Abstract

Background: Infections are a major clinical problem in the management of multiple myeloma (MM) due to both disease and treatment related factors. Measures to prevent infection, such as vaccination, are therefore of paramount importance in the clinical care of MM patients. Data on vaccine-preventable infections in MM treated with modern therapy is sparse.

Published
2023
Full Text
View/download PDF

170. Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Author

Blimark, Cecilie Hveding, Carlson, Kristina, Day, Christopher, Einarsdottir, Sigrun, Juliusson, Gunnar, Karma, Moshtak, Knut-Bojanowska, Dorota, Larfors, Gunnar, Turesson, Ingemar, Villegas Scivetti, Mariana, and Sverrisdottir, Ingigerdur

Abstract

Introduction

Published
2023
Full Text
View/download PDF

171. The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Author

Al-Sawaf, Othman, Fürstenau, Moritz, Giza, Adam, Robrecht, Sandra, Von Tresckow, Julia, Fink, Anna Maria, Simon, Florian, Tausch, Eugen, Schneider, Christof, Sivcheva, Liliya, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah R., Juliusson, Gunnar, Da Cunha-Bang, Caspar, Illmer, Thomas, Gregor, Michael, Thornton, Patrick, Janssens, Ann, Tadmor, Tamar, Lindström, Vesa, Staber, Philipp Bernhard, Levin, Mark-David, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Ritgen, Matthias, Stilgenbauer, Stephan, Kater, Arnon P., Niemann, Carsten Utoft, Fischer, Kirsten, Eichhorst, Barbara F., and Hallek, Michael

Abstract

Introduction

Published
2023
Full Text
View/download PDF

172. The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Author

Ngai, Lok Lam, Hanekamp, Diana, Kelder, Angèle, Scholten, Willemijn, Carbaat-Ham, Jannemieke, Fayed, Mona M.H.E, Snel, Alexander N., Bachas, Costa, Tettero, Jesse M., Mocking, Tim R., Van Der Velden, Vincent H.J., Slomp, Jennichjen, Hobo, Willemijn, Breems, Dimitri, Fischer, Thomas, Gjertsen, Bjorn T., Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J. M., Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C., van de Loosdrecht, Arjan A., Ossenkoppele, Gert, and Cloos, Jacqueline

Abstract

Clinical decision-making based on measurable residual disease (MRD) in acute myeloid leukemia (AML) is steadily increasing; therefore, accurate MRD results are imperative. Multi-parameter flow cytometry (MFC) is often used due to wide availability, particularly when no suitable mutation is present. Two approaches are most common in MFC-MRD: 1. Leukemia-associated immunophenotype (LAIP) approach, in which the aberrant phenotype is identified at diagnosis and tracked during follow-up. 2. Different-from-Normal (DfN) approach, in which aberrant surface antigen expression patterns not present in normal bone marrow (empty spaces in 2D dot plots) are identified at follow-up. The LAIP approach is sensitive, but does not consider immunophenotypic shifts and cannot be used when no LAIP is identified at diagnosis or when a diagnosis sample is unavailable. The DfN approach can detect these shifts, but ample expertise is needed to determine a malignant population. In the ELN-DAVID AML-MRD guidelines 2022, it is recommended to use the combination of the LAIP approach and the DfN approach to use the advantages of both approaches. In the HOVON-SAKK132 (HO132), the MRD was based on the combination of MFC-MRD and NPM1RQ-PCR. Initially, the MFC-MRD in this study was based on the LAIP approach. However, the complete MFC panel (four 8-color tubes) published by Cloos et al. (J.Vis.Exp, 2018) was used for measuring MRD during follow-up. Therefore in this study, we had the unique opportunity to retrospectively analyze the samples after induction cycle 2 (C2) of patients in complete remission (CR/CRi) and determine additional MRD results with the LAIP-based-DfN approach.

Published
2023
Full Text
View/download PDF

179. EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player

Author

Noerenberg*, Daniel, primary, Young*, Emma, additional, Ljungström, Viktor, additional, Mansouri, Larry, additional, Plevova, Karla, additional, Baliakas, Panagiotis, additional, Blakemore, Stuart, additional, Rossi, Davide, additional, Clifford, Ruth, additional, Navrkalova, Veronika, additional, Sutton, Lesley-Ann, additional, Smedby, Karin E, additional, Juliusson, Gunnar, additional, Belessi, Chrysoula, additional, Panagiotidis, Panagiotis, additional, Chiorazzi, Nicholas, additional, Davi, Frederic, additional, Langerak, Anton W., additional, Schuh, Anna, additional, Gaidano, Gianluca, additional, Strefford, Jonathan C, additional, Ghia, Paolo, additional, Stamatopoulos, Kostas, additional, Pospisilova, Sarka, additional, Zenz, Thorsten, additional, Rosenquist**, Richard, additional, and Damm**, Frederik, additional

Published
2015
Full Text
View/download PDF

180. ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome

Author

Navrkalova, Veronika, primary, Young, Emma, additional, Baliakas, Panagiotis, additional, Radova, Lenka, additional, Plevova, Karla, additional, Sutton, Lesley-Ann, additional, Mansouri, Larry, additional, Ljungstrom, Viktor, additional, Ntoufa, Stavroula, additional, Davis, Zadie, additional, Juliusson, Gunnar, additional, Smedby, Karin E, additional, Belessi, Chrysoula, additional, Panagiotidis, Panagiotis, additional, Davi, Frederic, additional, Langerak, Anton W., additional, Ghia, Paolo, additional, Strefford, Jonathan C, additional, Oscier, David G, additional, Stamatopoulos, Kostas, additional, Pospisilova, Sarka, additional, Rosenquist, Richard, additional, and Trbusek, Martin, additional

Published
2015
Full Text
View/download PDF

181. Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014

Author

Juliusson, Gunnar, primary, Lazarevic, Vladimir, additional, Antunovic, Petar, additional, Derolf, Asa Rangert, additional, Garelius, Hege, additional, Lehmann, Sören, additional, Myhr-Eriksson, Kristina, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Wahlin, Anders, additional, Wennström, Lovisa, additional, and Höglund, Martin, additional

Published
2015
Full Text
View/download PDF

182. Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry

Author

Deneberg, Stefan, primary, Lundin, Ebba, additional, Lazarevic, Vladimir, additional, Benson, Lina, additional, Uggla, Bertil, additional, Antunovic, Petar, additional, Mollgard, Lars, additional, Lehmann, Sören, additional, Juliusson, Gunnar, additional, Höglund, Martin, additional, and Derolf, Asa Rangert, additional

Published
2015
Full Text
View/download PDF

183. CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, additional, Agathangelidis, Andreas, additional, Hadzidimitriou, Anastasia, additional, Sutton, Lesley-Ann, additional, Minga, Eva, additional, Tausch, Eugen, additional, Yan, Xiao J., additional, Shanafelt, Tait D., additional, Plevova, Karla, additional, Boudjogra, Myriam, additional, Rossi, Davide, additional, Davis, Zadie, additional, Navarro, Alba, additional, Sandberg, Yorick, additional, Vojdeman, Fie Juhl, additional, Scarfo, Lydia, additional, Stavroyianni, Niki, additional, Sudarikov, Andrey B., additional, Veronese, Silvio, additional, Tzenou, Tatiana, additional, Karan-Djurasevic, Teodora, additional, Catherwood, Mark, additional, Kienle, Dirk, additional, Chatzouli, Maria, additional, Facco, Monica, additional, Bahlo, Jasmin, additional, Pedersen, Lone Bredo, additional, Mansouri, Larry, additional, Smedby, Karin E, additional, Chu, Charles C, additional, Giudicelli, Véronique, additional, Lefranc, Marie-Paule, additional, Panagiotidis, Panagiotis, additional, Juliusson, Gunnar, additional, Anagnostopoulos, Achilles, additional, Antic, Darko, additional, Trentin, Livio, additional, Montillo, Marco, additional, Niemann, Carsten, additional, Döhner, Hartmut, additional, Langerak, Anton W., additional, Darzentas, Nikos, additional, Pospisilova, Sarka, additional, Hallek, Michael, additional, Campo, Elias, additional, Chiorazzi, Nicholas, additional, Oscier, David, additional, Gaidano, Gianluca, additional, Belessi, Chrysoula, additional, Jelinek, Diane F., additional, Stilgenbauer, Stephan, additional, Davi, Frederic, additional, Rosenquist, Richard, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2015
Full Text
View/download PDF

188. Incidence, diagnostic, treatment and outcome of patients diagnosed with cancer of the pancreas during 1986–2009: a population-based study.

Author

Jonsdottir, Sara B., Juliusson, Gunnar, Kristinsson, Jon Ö., Hreinsson, Johann P., Jonasson, Jon G., and Björnsson, Einar S.

Subjects
*PANCREATIC cancer, *ADENOCARCINOMA, *TRANSURETHRAL prostatectomy, *DISEASE incidence, *DIAGNOSIS
Abstract

Objective:Limited data exist on the changes in the epidemiology of pancreatic cancer and outcomes over the last decades in population-based cohorts. We aimed to compare the incidence of pancreatic cancer, diagnostic, treatment and survival among patients diagnosed over the period 1986–2009. Materials and methods:A retrospective, nationwide, population-based study. All patients diagnosed with pancreatic cancer in Iceland in two periods, 1986–1997 (P1) and 1998–2009 (P2) were identified through the Icelandic Cancer Registry and relevant clinical information obtained from medical records. Results:A total of 645 patients were identified, 296 in P1 and 349 in P2 (NS). The incidence during P1 was 6.8 per 100,000 inhabitants and 6.2 during P2 (NS). Among biopsy-proven cancers, adenocarcinoma was diagnosed in 89% of the cases in P1 and in P2 in 93% of the cases. Overall 38 (14%) in P1 underwent resection and 22 (7%) in P2 (p < .0004). Patients diagnosed in P2 had longer survival at 6 months (p = .015, log-rank test) and one year (p = .0206) after diagnosis. A total of 4/296 (1.4%) in P1 survived more than 5 years and 3/349 (0.9%) in P2 (NS). Conclusions:The incidence among patients with pancreatic cancer in Iceland did not show major changes during the last 20 years. Diagnostic approach has changed considerably demonstrating more patients that are not ‘resectable’. Survival rate at 6 months and one year has improved over the last two decades whereas the 5-year prognosis has not improved. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

190. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia

Author

Ågerstam, Helena, primary, Karlsson, Christine, additional, Hansen, Nils, additional, Sandén, Carl, additional, Askmyr, Maria, additional, von Palffy, Sofia, additional, Högberg, Carl, additional, Rissler, Marianne, additional, Wunderlich, Mark, additional, Juliusson, Gunnar, additional, Richter, Johan, additional, Sjöström, Kjell, additional, Bhatia, Ravi, additional, Mulloy, James C., additional, Järås, Marcus, additional, and Fioretos, Thoas, additional

Published
2015
Full Text
View/download PDF

191. Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia

Author

Lazarevic, Vladimir, primary, Rosso, Aldana, additional, Juliusson, Gunnar, additional, Antunovic, Petar, additional, Rangert-Derolf, Åsa, additional, Lehmann, Sören, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Wennström, Lovisa, additional, Wahlin, Anders, additional, Höglund, Martin, additional, and Johansson, Bertil, additional

Published
2015
Full Text
View/download PDF

192. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia

Author

Mansouri, Larry, primary, Sutton, Lesley-Ann, additional, Ljungström, Viktor, additional, Bondza, Sina, additional, Arngården, Linda, additional, Bhoi, Sujata, additional, Larsson, Jimmy, additional, Cortese, Diego, additional, Kalushkova, Antonia, additional, Plevova, Karla, additional, Young, Emma, additional, Gunnarsson, Rebeqa, additional, Falk-Sörqvist, Elin, additional, Lönn, Peter, additional, Muggen, Alice F., additional, Yan, Xiao-Jie, additional, Sander, Birgitta, additional, Enblad, Gunilla, additional, Smedby, Karin E., additional, Juliusson, Gunnar, additional, Belessi, Chrysoula, additional, Rung, Johan, additional, Chiorazzi, Nicholas, additional, Strefford, Jonathan C., additional, Langerak, Anton W., additional, Pospisilova, Sarka, additional, Davi, Frederic, additional, Hellström, Mats, additional, Jernberg-Wiklund, Helena, additional, Ghia, Paolo, additional, Söderberg, Ola, additional, Stamatopoulos, Kostas, additional, Nilsson, Mats, additional, and Rosenquist, Richard, additional

Published
2015
Full Text
View/download PDF

194. Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

Author

Roghanian, Ali, primary, Teige, Ingrid, additional, Mårtensson, Linda, additional, Cox, Kerry L., additional, Kovacek, Mathilda, additional, Ljungars, Anne, additional, Mattson, Jenny, additional, Sundberg, Annika, additional, Vaughan, Andrew T., additional, Shah, Vallari, additional, Smyth, Neil R., additional, Sheth, Bhavwanti, additional, Chan, H.T. Claude, additional, Li, Zhan-Chun, additional, Williams, Emily L., additional, Manfredi, Giusi, additional, Oldham, Robert J., additional, Mockridge, C. Ian, additional, James, Sonya A., additional, Dahal, Lekh N., additional, Hussain, Khiyam, additional, Nilsson, Björn, additional, Verbeek, J. Sjef, additional, Juliusson, Gunnar, additional, Hansson, Markus, additional, Jerkeman, Mats, additional, Johnson, Peter W.M., additional, Davies, Andrew, additional, Beers, Stephen A., additional, Glennie, Martin J., additional, Frendéus, Björn, additional, and Cragg, Mark S., additional

Published
2015
Full Text
View/download PDF

195. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry

Author

Hulegårdh, Erik, primary, Nilsson, Christer, additional, Lazarevic, Vladimir, additional, Garelius, Hege, additional, Antunovic, Petar, additional, Rangert Derolf, Åsa, additional, Möllgård, Lars, additional, Uggla, Bertil, additional, Wennström, Lovisa, additional, Wahlin, Anders, additional, Höglund, Martin, additional, Juliusson, Gunnar, additional, Stockelberg, Dick, additional, and Lehmann, Sören, additional

Published
2015
Full Text
View/download PDF

196. Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups

Author

Beksac, Meral, primary, Waage, Anders, additional, Bringhen, Sara, additional, Kristinsson, Sigurdur Y., additional, Sucak, Gülsan Türköz, additional, Gimsing, Peter, additional, Lupparelli, Giulia, additional, Fıratlı-Tuğlular, Tulin, additional, Juliusson, Gunnar, additional, Turesson, Ingemar, additional, and Palumbo, Antonio, additional

Published
2015
Full Text
View/download PDF

198. Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-κB Deregulation in Aggressive Chronic Lymphocytic Leukemia

Author

Mansouri, Larry, primary, Sutton, Lesley-Ann, additional, Ljungstrom, Viktor, additional, Bondza, Sina, additional, Arngarden, Linda, additional, Bhoi, Sujata, additional, Larsson, Jimmy, additional, Cortese, Diego, additional, Kalushkova, Antonia, additional, Gunnarsson, Rebeqa, additional, Young, Emma, additional, Falk-Sorqvist, Elin, additional, Plevova, Karla, additional, Muggen, Alice, additional, Yan, Xiao-Jie, additional, Sander, Birgitta, additional, Enblad, Gunilla, additional, Smedby, Karin E, additional, Juliusson, Gunnar, additional, Belessi, Chrysoula, additional, Chiorazzi, Nicholas, additional, Strefford, Jonathan C, additional, Langerak, Anton W, additional, Pospisilova, Sarka, additional, Davi, Frederic, additional, Hellstrom, Mats, additional, Jernberg Wiklund, Helena, additional, Ghia, Paolo, additional, Soderberg, Ola, additional, Stamatopoulos, Kostas, additional, Nilsson, Mats, additional, and Rosenquist, Richard, additional

Published
2014
Full Text
View/download PDF

199. Clinical Impact of Stereotyped Antigen Receptors in Chronic Lymphocytic Leukemia

Author

Baliakas, Panagiotis, primary, Hadzidimitriou, Anastasia, additional, Sutton, Lesley-Ann, additional, Minga, Evangelia, additional, Agathangelidis, Andreas, additional, Tsanousa, Athina, additional, Scarfo, Lydia, additional, Davis, Zadie, additional, Yan, Joy, additional, Shanafelt, Tait D., additional, Plevova, Karla, additional, Sandberg, Yorick, additional, Vojdeman, Fie Juhl, additional, Boudjoghra, Myriam, additional, Tzenou, Tatiana, additional, Chatzouli, Maria, additional, Chu, Charles C., additional, Veronese, Silvio, additional, Gardiner, Anne Catherine, additional, Mansouri, Larry, additional, Smedby, Karin E, additional, Pedersen, Lone, additional, Moreno, Denis, additional, van Lom, Kirsten, additional, Giudicelli, Veronique, additional, Francova, Hana, additional, Nguyen-Khac, Florence, additional, Panagiotidis, Panagiotis, additional, Juliusson, Gunnar, additional, Angelis, Lefteris, additional, Anagnostopoulos, Achilles, additional, Lefranc, Marie-Paule, additional, Facco, Monica, additional, Trentin, Livio, additional, Catherwood, Mark, additional, Montillo, Marco, additional, Geisler, Christian H, additional, Langerak, Anton W, additional, Pospisilova, Sarka, additional, Chiorazzi, Nicholas, additional, Oscier, David, additional, Jelinek, Diane F., additional, Darzentas, Nikos, additional, Belessi, Chrysoula, additional, Davi, Frederic, additional, Rosenquist, Richard, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2014
Full Text
View/download PDF

200. Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013

Author

Juliusson, Gunnar, primary, Lazarevic, Vladimir, additional, Lehmann, Sören, additional, Derolf, Åsa Rangert, additional, Möllgård, Lars, additional, Garelius, Hege, additional, Wennström, Lovisa, additional, Uggla, Bertil, additional, Antunovic, Petar, additional, Myhr-Eriksson, Kristina, additional, Wahlin, Anders, additional, and Höglund, Martin, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results